Intratumoral Administration of Recombinant Human Interleukin 12 in Head and Neck Squamous Cell Carcinoma Patients Elicits A T-Helper 1 Profile in the Locoregional Lymph Nodes

Clinical Cancer Research

Volumn 10, Issue 8, 2004, Pages 2626-2635

  Van Herpen, Carla M ^a   Looman, Maaike ^a   Zonneveld, Marijke ^a   Scharenborg, Nicole ^a   De Wilde, Peter C ^a   Van De Locht, Louis ^a   Merkx, Matthias A W ^a   Adema, Gosse J ^a   De Mulder, Pieter H ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; MESSENGER RNA; RECOMBINANT INTERLEUKIN 12;

ADULT; AGED; ARTICLE; BLOOD; CANCER INFILTRATION; CANCER PATIENT; CELL COUNT; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ADMINISTRATION ROUTE; DRUG EFFECT; DRUG SCREENING; FATIGUE; FEMALE; FEVER; HEAD AND NECK CARCINOMA; HUMAN; IMMUNE RESPONSE; INJECTION; LIVER TOXICITY; LYMPH NODE; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; LYMPHOCYTOPENIA; MALE; METABOLIC ACIDOSIS; MONOCYTE; MYALGIA; NATURAL KILLER CELL; NAUSEA; PERIPHERAL BLOOD MONONUCLEAR CELL; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; TH1 CELL; TH2 CELL; TOXICITY;

ADULT; AGED; AREA UNDER CURVE; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CYTOKINES; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; INTERFERON TYPE II; INTERLEUKIN-10; INTERLEUKIN-12; KINETICS; LEUKOCYTES, MONONUCLEAR; LYMPH NODES; LYMPHOCYTE SUBSETS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TH1 CELLS; TIME FACTORS; TREATMENT OUTCOME;

EID: 1942502672     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0304     Document Type: Article

References (38)

1. Whiteside TL, Chikamatsu K, Nagashima S, Okada K. Antitumor effects of cytolytic T lymphocytes (CTL) and natural killer (NK) cells in head and neck cancer. Anticancer Res 1996;16:2357-64.
2. Finke J, Ferrone S, Frey A, Mufson A, Ochoa A. Where have all the T cells gone? Mechanisms of immune evasion by tumors. Immunol Today 1999;20:158-60.
3. Reichert TE, Strauss L, Wagner EM, Gooding W, Whiteside TL. Signaling abnormalities, apoptosis, and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma. Clin Cancer Res 2002;8:3137-45.
4. Gately MK, Desai BB, Wolitzky AG, et al. Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor). J Immunol 1991;147:874-82.
5. Kobayashi M, Fitz L, Ryan M, et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med 1989;170:827-45.
6. Trinchieri G. Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood 1994;84:4008-27.
7. Brunda MJ. Interleukin-12. J Leukoc Biol 1994;55:280-8.
8. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003;3:133-46.
9. Banks RE, Patel PM, Selby PJ. Interleukin 12: a new clinical player in cytokine therapy. Br J Cancer 1995;71:655-9.
10. Voest EE, Kenyon BM, O'Reilly MS, et al. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst (Bethesda) 1995;87:581-6.
11. Sgadari C, Angiolillo AL, Tosato G. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood 1996;87:3877-82.
12. Brunda MJ, Luistro L, Warrier RR, et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 1993;178:1223-30.
13. Nastala CL, Edington HD, McKinney TG, et al. Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J Immunol 1994;153:1697-706.
14. Atkins MB, Robertson MJ, Gordon M, et al. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res 1997;3:409-17.
15. Bajetta E, Del Vecchio M, Mortarini R, et al. Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanoma. Clin Cancer Res 1998;4:75-85.
16. Motzer RJ, Rakhit A, Schwartz LH, et al. Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma. Clin Cancer Res 1998;4:1183-91.
17. Robertson MJ, Cameron C, Atkins MB, et al. Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer. Clin Cancer Res 1999;5:9-16.
18. Portielje JE, Kruit WH, Schuler M, et al. Phase I study of subcutaneously administered recombinant human interleukin 12 in patients with advanced renal cell cancer. Clin Cancer Res 1999;5:3983-9.
19. Gollob JA, Mier JW, Veenstra K, et al. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-γ induction is associated with clinical response. Clin Cancer Res 2000;6:1678-92.
20. Leonard JP, Sherman ML, Fisher GL, et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-γ production. Blood 1997;90:2541-8.
21. Motzer RJ, Rakhit A, Thompson JA, et al. Randomized multicenter Phase II trial of subcutaneous recombinant human interleukin-12 versus interferon-α2a for patients with advanced renal cell carcinoma. J Interferon Cytokine Res 2001;21:257-63.
22. Hurteau JA, Blessing JA, DeCesare SL, Creasman WT. Evaluation of recombinant human interleukin-12 in patients with recurrent or refractory ovarian cancer: a gynecologic oncology group study. Gynecol Oncol 2001;82:7-10.
23. Coughlin CM, Wysocka M, Trinchieri G, Lee WM. The effect of interleukin 12 desensitization on the antitumor efficacy of recombinant interleukin 12. Cancer Res 1997;57:2460-7.
24. van Herpen CM, Huijbens R, Looman M, et al. Pharmacokinetics and immunological aspects of a Phase Ib study with intratumoral administration of recombinant human interleukin-12 in patients with head and neck squamous cell carcinoma: a decrease of T-bet in PBMCs. Clin Cancer Res 2003;9:2950-6.
25. Jansen PM, van der Pouw Kraan TC, de Jong IW, et al. Release of interleukin-12 in experimental Escherichia coli septic shock in baboons: relation to plasma levels of interleukin-10 and interferon-γ. Blood 1996;87:5144-51.
26. Vissers JL, Hartgers FC, Lindhout E, et al. Quantitative analysis of chemokine expression by dendritic cell subsets in vitro and in vivo. J Leukoc Biol 2001;69:785-93.
27. Kaplan E, Meyer P. Nonparametric estimation for incomplete observation. J Am Stat Assoc 1958;53:457-81.
28. Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J Clin Oncol 1983;1:710-9.
29. Gately MK, Warrier RR, Honasoge S, et al. Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocyte activity and induces production of IFN-γ in vivo. Int Immunol 1994;6:157-67.
30. Shi F, Rakhmilevich AL, Heise CP, et al. Intratumoral injection of interleukin-12 plasmid DNA, either naked or in complex with cationic lipid, results in similar tumor regression in a murine model. Mol Cancer Ther 2002;1:949-57.
31. Topp MS, Riddell SR, Akatsuka Y, et al. Restoration of CD28 expression in CD28-CD8+ memory effector T cells reconstitutes antigen-induced IL-2 production. J Exp Med 2003;198:947-55.
32. Elloso MM, Scott P. Differential requirement of CD28 for IL-12 receptor expression and function in CD4(+) and CD8(+) T cells. Eur J Immunol 2001;31:384-95.
33. van Wely CA, Beverley PC, Brett SJ, Britten CJ, Tite JP. Expression of L-selectin on Th1 cells is regulated by IL-12. J Immunol 1999;163:1214-21.
34. Salio M, Cella M, Vermi W, et al. Plasmacytoid dendritic cells prime IFN-γ-secreting melanoma-specific CD8 lymphocytes and are found in primary melanoma lesions. Eur J Immunol 2003;33:1052-62.
35. Rakhit A, Yeon MM, Ferrante J, et al. Down-regulation of the pharmacokinetic-pharmacodynamic response to interleukin-12 during long-term administration to patients with renal cell carcinoma and evaluation of the mechanism of this "adaptive response" in mice. Clin Pharmacol Ther 1999;65:615-29.
36. Portielje JE, Lamers CH, Kruit WH, et al. Repeated administrations of interleukin (IL)-12 are associated with persistently elevated plasma levels of IL-10 and declining IFN-γ, tumor necrosis factor-α, IL-6, and IL-8 responses. Clin Cancer Res 2003;9:76-83.
37. Mocellin S, Panelli MC, Wang E, Nagorsen D, Marincola F. The dual role of IL-10. Trends Immunol 2003;24:36-43.
38. Nabors GS, Afonso LC, Farrell JP, Scott P. Switch from a type 2 to a type 1 T helper cell response and cure of established Leishmania major infection in mice is induced by combined therapy with interleukin 12 and Pentostam. Proc Natl Acad Sci USA 1995;92:3142-6.